| Identification | Back Directory | [Name]
2,2-Dichloro-N-(3-chloro-4-fluorophenyl)acetamide | [CAS]
349106-80-5 | [Synonyms]
LDCA
2,2-Dichloro-N-(3-chloro-4-fluorophenyl)acetamide
Acetamide, 2,2-dichloro-N-(3-chloro-4-fluorophenyl)- | [Molecular Formula]
C8H5Cl3FNO | [MOL File]
349106-80-5.mol | [Molecular Weight]
256.49 |
| Chemical Properties | Back Directory | [Boiling point ]
366.4±42.0 °C(Predicted) | [density ]
1.585±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9.51±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression[1]. | [in vivo]
LDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma[1]. | Animal Model: | melanoma tumor model[1] | | Dosage: | 2 mg/kg | | Administration: | 2 mg/kg, iv., the 6th day, once | | Result: | Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena. |
| [References]
[1] Saha, Suchandrima, et al. The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks. RSC Advances, 7(84), 53322–53333. doi:10.1039/c7ra08625c. |
|
|